{"doi":"10.1016/j.jacc.2004.06.060","title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension","abstract":null,"journal":"Journal of the American College of Cardiology","year":2004,"id":26928,"datarank":15.231979350513914,"base_score":5.655991810819852,"endowment":5.655991810819852,"self_citation_contribution":0.8483987716229779,"citation_network_contribution":14.383580578890935,"self_endowment_contribution":0.8483987716229779,"citer_contribution":14.383580578890935,"corpus_percentile":null,"corpus_rank":null,"citation_count":285,"citer_count":200,"citers_with_citation_signal":200,"citers_with_endowment":200,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":154642,"name":"Robert Voswinckel","orcid":null,"position":1,"is_corresponding":false},{"id":2930,"name":"Frank Reichenberger","orcid":null,"position":2,"is_corresponding":false},{"id":154643,"name":"Horst Olschewski","orcid":null,"position":3,"is_corresponding":false},{"id":154644,"name":"Peter Haredza","orcid":null,"position":4,"is_corresponding":false},{"id":154645,"name":"Burcu Karadaş","orcid":null,"position":5,"is_corresponding":false},{"id":154646,"name":"Ralph T. Schermuly","orcid":null,"position":6,"is_corresponding":false},{"id":153713,"name":"Norbert Weissmann","orcid":null,"position":7,"is_corresponding":false},{"id":89032,"name":"Werner Seeger","orcid":"0000-0003-1946-0894","position":8,"is_corresponding":false},{"id":153718,"name":"Friedrich Grimminger","orcid":null,"position":9,"is_corresponding":false},{"id":154641,"name":"Hossein A. Ghofrani","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":5.655991810819852,"endowment":5.655991810819852,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"15464333","pmcid":null,"openalex_id":"https://openalex.org/W2035736227","authors":[],"funders":[],"total_grants":0,"fwci":22.6135,"citation_percentile":0.99688781,"influential_citations":10,"citation_trend":[{"year":2012,"count":22},{"year":2013,"count":13},{"year":2014,"count":15},{"year":2015,"count":23},{"year":2016,"count":3},{"year":2017,"count":9},{"year":2018,"count":5},{"year":2019,"count":9},{"year":2020,"count":6},{"year":2021,"count":3},{"year":2022,"count":1},{"year":2023,"count":4},{"year":2024,"count":1},{"year":2025,"count":6}],"oa_status":"closed","license":"https://www.elsevier.com/open-access/userlicense/1.0/","oa_locations":[{"url":"https://doi.org/10.1016/j.jacc.2004.06.060","host_type":"BRONZE"},{"url":"https://api.elsevier.com/content/article/PII:S0735109704013622?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0735109704013622?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/15464333","host_type":"repository"}],"fields_of_study":["Pulmonary Hypertension Research and Treatments","Phosphodiesterase function and regulation","Sexual function and dysfunction studies","Medicine","3',5'-Cyclic-GMP Phosphodiesterases","Administration, Oral","Adult","Aged","Carbolines","Cyclic Nucleotide Phosphodiesterases, Type 5","Drug Administration Schedule","Enzyme Inhibitors","Female","Humans","Hypertension, Pulmonary","Imidazoles","Male","Middle Aged","Oxygen","Phosphoric Diester Hydrolases","Piperazines","Prospective Studies","Purines","Sildenafil Citrate","Sulfones","Tadalafil","Treatment Outcome","Triazines","Vardenafil Dihydrochloride","Vascular Resistance","Vasodilator Agents"],"mesh_terms":["Tadalafil","Sildenafil Citrate","Vardenafil Dihydrochloride","Administration, Oral","Adult","Aged","Carbolines","Drug Administration Schedule","Enzyme Inhibitors","Female","Humans","Hypertension, Pulmonary","Imidazoles","Male","Middle Aged","Oxygen","Phosphoric Diester Hydrolases","Piperazines","Prospective Studies","Purines","Sulfones","Triazines","Vascular Resistance","Vasodilator Agents","3',5'-Cyclic-GMP Phosphodiesterases","Treatment Outcome","Cyclic Nucleotide Phosphodiesterases, Type 5"],"keywords":["Tadalafil","Sildenafil","Vardenafil","Medicine","cGMP-specific phosphodiesterase type 5","Pulmonary hypertension","Erectile dysfunction","Hemodynamics","Oxygenation","Vascular resistance","Anesthesia","Internal medicine","Pharmacology","Cardiology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T16:04:07.869510Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}